Metabolically driven, chronic, low-grade inflammation has a crucial role in the pathogenesis of obesity and type 2 diabetes, and multiple stress-signaling cascades link insulin resistance and the immune response. An approved immunomodulatory drug is now shown to inhibit the kinases IKKε and TBK1, suppress inflammation and improve metabolic homeostasis in mouse models of obesity (pages 313–321).
- Ediz S. Calay
- Gökhan S. Hotamisligil